Dr Reddy's Laboratories. shareholding pattern

DRREDDY

1186.1

7.40 (0.63%)
Last updated on 2 Feb, 2026 | 09:20 IST
alert_iconwatchlist_icon
BUYSELL

alert_iconThe current prices are delayed, login to your account for live prices

Dr Reddy's Laboratories. Shareholding Pattern

  • 2018-19
  • 2020-21
  • 2022-23
  • 2023-24
  • 2024-25
  • 2016-17
  • 2025-26
  • 2021-22
  • 2019-20
  • 2017-18
Total Promoters
Segment
Percent

Total Promoters

26.64%

Mutual Fund

13.87%

Insurance

14.05%

Foreign Institutional Investors

22.34%

Domestic Institutional Investors

2.52%

Retail

9.72%

Others

10.86%

Total Promoters
MAR '25
26.64%
JUN '25
26.64%
SEP '25
26.64%
DEC '25
26.64%

Summary

For Year 2025-26, Dr Reddy's Laboratories. reports the following shareholding: Total Promoters at 26.64%, Mutual Fund at 13.87%, Insurance at 14.05%, Foreign Institutional Investors at 22.34%, Domestic Institutional Investors at 2.52%, and Retail at 9.72%. This breakdown provides a quick snapshot of ownership distribution for Dr Reddy's Laboratories. in 2025-26.

Dr Reddy's Laboratories. FAQs

As of 02-2026, the promoter shareholding in Dr Reddy's Laboratories. stands at 26.64% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Dr Reddy's Laboratories. is 22.34% and 2.52% respectively.

The retail shareholding of the Dr Reddy's Laboratories. is 9.72%.

Changes in shareholding patterns of Dr Reddy's Laboratories. can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Dr Reddy's Laboratories. are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.